Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions
Gastrointestinal CancerGastric CancerEsophageal CancerAppendiceal Cancer
Interventions
DRUG

CYTALUX™ (pafolacianine)

All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.

Trial Locations (1)

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

On Target Laboratories, LLC

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER

NCT07124351 - Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) | Biotech Hunter | Biotech Hunter